Novartis’ heart drug serelaxin fails in key trial
Novartis is considering the future of serelaxin after the drug hit another setback failing to meet key goals in a late-stage study involving patients with acute heart failure.
Read More
Tag: serelaxin
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
